Rezultati pretrage - Pariser, David
- Prikaz rezultata 1 – 20 od 26
- Idi na sljedeću stranicu
-
1
-
2
-
3
Selected Musculoskeletal and Performance Characteristics of Members of a Women's Professional Football Team: Application of a Pre-participation Examination od Nett, Beth, Brosky, Joseph A., Velarde, Lynnuel, Pariser, David P., Boyce, David A.
Izdano 2010Tekst -
4
-
5
-
6
A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm od Strober, Bruce, Pariser, David, Deren-Lewis, Ann, Dickerson, Tobin J., Lebwohl, Mark, Menter, Alan
Izdano 2021Tekst -
7
Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials od Pariser, David M., Hebert, Adelaide A., Drew, Janice, Quiring, John, Gopalan, Ramanan, Glaser, Dee Anna
Izdano 2018Tekst -
8
Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propion... od Bhatia, Neal D., Pariser, David M., Kircik, Leon, Lin, Tina, Harris, Susan, Mathew, Lindsey, Pillai, Radhakrishnan
Izdano 2018Tekst -
9
Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies od Pariser, David, Frankel, Ellen, Schlessinger, Joel, Poulin, Yves, Vender, Ronald, Langley, Richard G., Meng, Xiangyi, Guana, Adriana, Nyirady, Judit
Izdano 2017Tekst -
10
Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study od Pariser, David M., Green, Lawrence J., Lain, Edward L., Schmitz, Carsten, Chinigo, Amy S., McNamee, Brian, Berk, David R.
Izdano 2019Tekst -
11
Long‐term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44‐week open‐label... od Hebert, Adelaide A., Glaser, Dee Anna, Green, Lawrence, Hull, Cheryl, Cather, Jennifer, Drew, Janice, Gopalan, Ramanan, Pariser, David M.
Izdano 2020Tekst -
12
Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis od Valenzuela, Fernando, Papp, Kim A, Pariser, David, Tyring, Stephen K, Wolk, Robert, Buonanno, Marjorie, Wang, Jeff, Tan, Huaming, Valdez, Hernan
Izdano 2015Tekst -
13
Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis od Bruin, Gerard, Hasselberg, Anke, Koroleva, Irina, Milojevic, Julie, Calonder, Claudio, Soon, Rachel, Woessner, Ralph, Pariser, David M., Boutouyrie‐Dumont, Bruno
Izdano 2019Tekst -
14
Bimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A Pooled Safety Analysis of Six Randomized, Double-masked Clinical Trials od Wirta, David, Pariser, David M., Yoelin, Steven G., Arase, Seiji, McMichael, Amy, Weng, Emily, Mao, Cheri, Demos, George, Vandenburgh, Amanda
Izdano 2015Tekst -
15
Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials od Hebert, Adelaide A., Glaser, Dee Anna, Green, Lawrence, Werschler, William P., Forsha, Douglass W., Drew, Janice, Gopalan, Ramanan, Pariser, David M.
Izdano 2018Tekst -
16
A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis od Glaser, Dee Anna, Hebert, Adelaide A., Nast, Alexander, Werschler, William P., Green, Lawrence, Mamelok, Richard D., Quiring, John, Drew, Janice, Pariser, David M.
Izdano 2019Tekst -
17
Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis od Simpson, Eric, Eckert, Laurent, Gadkari, Abhijit, Mallya, Usha G., Yang, Min, Nelson, Lauren, Brown, Michelle, Reaney, Matt, Mahajan, Puneet, Guillemin, Isabelle, Boguniewicz, Mark, Pariser, David
Izdano 2019Tekst -
18
The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score od Papp, Kim A., Lebwohl, Mark G., Kircik, Leon H., Pariser, David M., Strober, Bruce, Krueger, Gerald G., Berk, David R., Navale, Lynn, Higham, Robert C.
Izdano 2021Tekst -
19
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results od Kimball, Alexa B., Rothman, Kenneth J., Kricorian, Gregory, Pariser, David, Yamauchi, Paul S., Menter, Alan, Teller, Craig F., Aras, Girish, Accortt, Neil A., Hooper, Michele, Rice, Kara Creamer, Gelfand, Joel M.
Izdano 2014Tekst -
20
Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE) od Bagel, Jerry, Nguyen, Tien Q., Lima, Hermenio, Jain, Neal, Pariser, David M., Hsu, Sylvia, Yosipovitch, Gil, Zhang, Haixin, Chao, Jingdong, Bansal, Shikha, Chen, Zhen, Richman, Daniel, Korotzer, Andrew, Ardeleanu, Marius
Izdano 2022Tekst